"Nanobased drug delivery PowerPoint"
Targeted drug delivery by nanoparticles and theranostics SRPA Leader: Rafi Korenstein Tel-Aviv University E-mail: firstname.lastname@example.org delivery routes nanocarriers targeting Strategic Goals • Develop activity that will lead to the formation of long term research collaboration with industry (e.g. initiation by STREP and IP in the 7th Framework Program of EC followed by industry supported research) • Form an expertise reference point for industry, research institutes and society Scientific General Goals (1) Development of new multifunctional targeted drug delivery systems: • Develop innovative nanoparticles and nanocapsules as drug carrier systems for new drugs • Examine novel approaches for enhancing the ability to pass the cell/tissue barriers (mucosal lining, air-blood barrier of the human lung, blood-brain barrier) • Explore novel targeting strategies (ppreferably combined with bioimaging capacity of the targeted areas) Scientific General Goals (2) • Investigate ways for enhanced uptake of carriers for intracellular targets. • Development and validation of in-vitro models mimicking the in-vivo characteristics of human tissues and organs for the examination of drug uptake and toxicity aiming to limit in-vivo animal testing. • Theranostics (diagnostics & therapeutics) – Integration of fast diagnostic devices and drug therapy involving a feedback loop to monitor and improve drug efficiency and to minimize side effects (individual therapy). Specific Goals • Cancer therapy - formation of integrated approach to metastatic cancer therapy through combined chemotherapy linked to nanocarriers and electrical accelerated uptake of the chemotherapy in the primary tumor • Active drug delivery – MEMS/NEMS devices for regulated drug delivery (Microchip-based drug delivery consisting of microfluidics combined with sensors • Drug delivery of proteins and peptides • Toxicology of nanaocarriers Advantages of nanoparticles as drug carriers Large surface-to-volume ratio resulting enhanced interaction sites Surface functionalization for targeting Suitable encapsulation Release drugs in controlled manner More efficient uptake by cells Active drug delivery MEMS/NEMS devices for regulated drug delivery (Microchip-based drug delivery consisting of microfluidics combined with sensors MEMS/NMEMS based devices Release of drug (alone or associated with a nanoparticle carrier) Sensing (electrical, optical or chemical) enabling closed loop drug delivery Drug delivery by implantable nano/micro devices (semi implantable) Development of 'smart' systems for the release of therapeutic agents by devices placed at appropriate sites: Concentration of therapeutic action exclusively or predominantly at a desired target site (targeting) Avoidance of barriers to the penetration thereby increase the efficacy of the therapeutic action Advantages of local drug release strategies over systhemic drug therapy • Lower doses required • Greater control over toxicity and bioavailability of dose • Extended duration of release • Possibilities to combine local and systemic drugs with different kinetics • Controlled release directly to site • Avoidance of systemic drug exposure General characteristics of the device Sensors (electrical, electrochemical, chemical, optical or other detection modes) Mode of drug release (e.g. feedback) Power (micro-bateries) Biocompatibility (through surface modification) Limitations • Fully implantable devices are restricted in the amount of drug to be released • The requirement of surgical procedure for implantation • Biofouling/biocompatibility Intersection Projects During the last annual meeting of N2L in Sitges (Barcellona) March 2006, the intersection on implantable drug delivery systems was discussed. The need of targeting on specific clinically oriented goals was discussed in a forum consisting of about 20 participants. In view of this discussion and taking into consideration the priorities of research in the area of drug delivery in the field of nanomedicine it has been decided to concentrate at present on two specific clinically oriented intersection topics: Diabetes Cancer therapy More details on these two intersection projects are available on the conference website.